Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
NASDAQ: SHPH · Real-Time Price · USD
3.440
-0.080 (-2.27%)
At close: Aug 25, 2026, 4:00 PM EDT
3.440
0.00 (0.00%)
After-hours: Aug 25, 2026, 5:38 PM EDT
Company Description
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to treat cancers.
It owns a pharmaceutical software artificial intelligence (AI) driven platform for molecular discovery and early-stage drug development.
The company was founded in 2012 and is headquartered in Gaithersburg, Maryland.
Shuttle Pharmaceuticals Holdings, Inc.
| Country | United States |
| Founded | 2012 |
| IPO Date | Aug 31, 2022 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Christopher Cooper |
Contact Details
Address: 401 Professional Drive, Suite 260 Gaithersburg, Maryland 20879 United States | |
| Phone | 240 403 4212 |
| Website | shuttlepharma.com |
Stock Details
| Ticker Symbol | SHPH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $8.13 |
| CIK Code | 1757499 |
| CUSIP Number | 825693500 |
| ISIN Number | US8256935003 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Ryan Trasolini | Co-Chief Executive Officer |
| Christopher Robert Cooper BBA, M.B.A. | Interim Co-Chief Executive Officer and Director |
| Dr. Milton Brown CSC, M.D., Ph.D. | Co-Founder |
| Dr. Mira Jung Ph.D. | Co-Founder and Chief Scientific Officer for Biology |
| Yuying Liang B.A., C.P.A. | Chief Financial Officer |
| Dr. Tyvin A. Rich M.D. | Chief Clinical Officer and Chief Medical Officer |
| Michael P. Vander Hoek | Vice President for Operations and Regulatory |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 17, 2026 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Aug 17, 2026 | 8-K/A | [Amend] Current report |
| Aug 13, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Aug 13, 2026 | DEF 14A | Other definitive proxy statements |
| Aug 3, 2026 | PRE 14A | Other preliminary proxy statements |
| Jul 1, 2026 | 8-K | Current Report |
| Jun 11, 2026 | 8-K | Current Report |
| May 27, 2026 | 8-K | Current Report |
| May 15, 2026 | D | Notice of Exempt Offering of Securities |
| May 15, 2026 | 10-Q | Quarterly Report |